Phase I/II Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Considering participating in a START clinical trial?
Study Summary
Assessment of the safety and efficacy of HLD-0915 as monotherapy in patients with metastatic castration resistant prostate cancer (mCRPC) that have progressed on prior systemic therapies, once a recommended dose for expansion (RDE) has been determined in Phase 1 of the trial.
To characterize the PK profile and assess clinical activity by PSA decline and objective response rate per RECIST and will explore ctDNA, tumor cell genetics, and PD biomarkers.
To evaluate the first-in-class RIPTAC therapeutic, HLD-0915 in patients with metastatic castration-resistant prostate cancer.
To evaluate monotherapy safety, tolerability, and clinical activity of orally administered HLD-0915 AR-BRD4 RIPTAC™ therapeutic in patients with mCRPC.
- Key
- All patients must meet the following criteria to be eligible for Phase 1 study participation:
- 1. Males of age 18 years at the time of signing the informed consent form (ICF).
- 2. Able to understand and voluntarily sign an informed consent document prior to any study-related assessments/procedures.
- 3. Patients must have histological, pathological, and/or cytological confirmation of adenocarcinoma of the prostate.
- 4. Patients must have prior orchiectomy and/or ongoing androgen-deprivation therapy and a castrate level of serum testosterone.
- 5. Patients must have progressed on prior line(s) of therapy.
- 6. Patients must have progressive mCRPC defined as having demonstrated PSA progression on the prior regimen. PSA progression may have occurred with or without accompanying radiographic progression.
- 7. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- 8. Life expectancy of at least 3 months.
- 9. Adequate hematological, renal, and hepatic function.
- 10. Able to swallow an oral medication.
- 11. Willing and able to adhere to the study visit schedule and other protocol requirements.
- 12. Patients on a stable bisphosphonate or denosumab regimen for 30 days prior to enrollment are eligible.
- Progressive mCRPC with rising PSA on prior treatment (and PSA ≥ 2
- ng/mL)
- • Prior treatment with at least ≥1 ARPI, and may have had ≤2 prior
- taxanes and ≤1 RLT
- • ECOG 0-1
- Patients with any of the following will be excluded from participation in Phase 1 of the study:
- 1. Has experienced a recent major bleed or has a known bleeding disorder.
- 2. Tumors exhibiting neuroendocrine or small cell carcinoma component by histopathology.
- 3. Receiving continuous corticosteroids at prednisone-equivalent dose of >10 mg/day.
- 4. Has received systemic anti-cancer therapy (cytotoxic chemotherapy, biologic agent, checkpoint inhibitors, or radiation therapy) or investigational drugs within 2 weeks prior to first dose of study drug with certain exceptions requiring longer washout periods.
- 5. History of myocardial infarction or unstable angina within 6 months prior to enrollment, or clinically significant cardiac disease.
- 6. Known clinically significant active or chronic infection.
- 7. Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease.
Clinical Study Information for Healthcare Providers
By clicking the button below you will find in-depth information about this clinical trial, including study design, primary and secondary endpoints, and more. This information is intended for healthcare professionals seeking to review the scientific and operational aspects of the study.